NCT07028125View on ClinicalTrials.gov

Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

PHASE4RecruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

January 31, 2029

Conditions
Renal Cell Carcinoma (Kidney Cancer)Metastatic Renal Cell CarcinomaLocally Advanced
Interventions
DRUG

cabozantinib and nivolumab

"cabozantinib and nivolumab according to the labelling indication, namely:~* CABOZANTINIB 40 mg per oral route once daily~* NIVOLUMAB 240 mg per intravenous route every 2 weeks~During this combined treatment, the digital monitoring system is used to collect weekly data on treatment tolerance by patient self-report."

Trial Locations (10)

Unknown

NOT_YET_RECRUITING

Centre Hospitalier d'Annecy, Annecy

RECRUITING

Institut Sainte Catherine, Avignon

NOT_YET_RECRUITING

Centre Hospitalier de Bayeux, Bayeux

RECRUITING

Centre François Baclesse, Caen

NOT_YET_RECRUITING

Polyclinique du Parc Elsan, Caen

NOT_YET_RECRUITING

Ghpso Creil, Creil

NOT_YET_RECRUITING

Centre Hospitalier de Lorient, Lorient

RECRUITING

GHR Mulhouse Sud Alsace, Mulhouse

NOT_YET_RECRUITING

CHU, Saint-Etienne

NOT_YET_RECRUITING

Centre Hospitalier de Tours, Tours

All Listed Sponsors
lead

Centre Francois Baclesse

OTHER